Antibody Drug Conjugate Market Booming CAGR 19% with Leading Players ImmunoGen, Genentech, Pfizer, Antikor – Ultimate Outlook Till 2023

Worldwide Deep Study of “Antibody Drug Conjugate Market” Available on MarketResearchFuture.com We are Providing Unique Information related Antibody Drug and also provide those Types Monoclonal Antibodies, Linker etc. - Outlook Till 2023

Antibody Drug Conjugate Market - Market Insights

These drug conjugates are regarded as the new age of therapeutic agents. The efficiency of the drug in treating diseases has propelled demand in the global market, and the trend is likely to perpetuate over the next few years. The effects of targeting specific cells coupled with the killing ability of cytotoxic drugs make this antibody drug conjugate the ideal choice for the treatment of various cancers.

The rising prevalence of cancer all across the globe has catapulted the antibody drug conjugate market on an upward trajectory. Additionally, the advancements in medical technologies are anticipated to drive the growth of the global market by enhancing the accuracy of the drug.

To Explore More, Get PDF Sample Copy @ https://www.marketresearchfuture.com/sample_request/1113

Increased investments in research & developments in the antibody drug conjugate market are further expected to augment the market size. Nevertheless, the high cost associated with the procedures is likely to hold the market growth through the projection period.

Antibody Drug Conjugate Market - Competitive Dashboard

Some of the key players profiled by MRFR are Seattle Genetics (U.S.), ImmunoGen, Inc. (U.S.), Roche Holding AG (Switzerland), Antikor (U.K.), Immunomedics (U.S.), Pfizer Inc. (U.S.), Celldex Therapeutics (U.S.), Millennium Pharmaceuticals (U.S.), AbbVie Inc. (U.S.), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.),  Bayer HealthCare (Germany),  Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (U.S.), Heidelberg Pharma (Germany), Oxford BioTherapeutics (U.S.), Mersana Therapeutics (U.S.), and Synthon (U.S.).

Antibody Drug Conjugate Market - Segmentation

By type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.

By application, the antibody drug conjugate market has been segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further sub-segmented into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).

By product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.

By technology, the antibody drug conjugate market has been segmented into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.

By end-user, the global antibody drug conjugate market is segmented into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113

Antibody Drug Conjugate Market - Industry Developments

In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo’s proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.

Antibody Drug Conjugate Market - Regional Analysis

By region, the global antibody drug conjugate market is segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas dominate the global market owing to technological innovations, manufacturing process advancements, the contribution of nanotechnology, etc. Led by the U.S., the region is anticipated to retain its pole position through the assessment period. Europe is likely to retain its second spot trailed by the Asia Pacific which is an emerging market for antibody drug conjugate.

Major Points from Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

Chapter 3. Research Methodology 

Chapter 4. Market Dynamics

Chapter 5. Market Factor Analysis

Chapter 6. Global Antibody Drug Conjugate Market, By Type

Chapter 7. Global Antibody Drug Conjugate Market, By Application

Chapter 8. Global Antibody Drug Conjugate Market, By Product

Chapter 9. Global Antibody Drug Conjugate Market, By Technology

Chapter 10. Global Antibody Drug Conjugate Market, By End-User

Chapter. 11 Global Antibody Drug Conjugate Market, By Region

Chapter 12 Company Landscape

Chapter 13 Company Profiles

Chapter 14 MRFR Conclusion

Chapter 15 Appendix

Check Discount @ https://www.marketresearchfuture.com/check-discount/1113

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.